Targeting PLK1 in myelodysplastic syndromes: The Role of Rigosertib in Precision Medicine
{{output}}
Rigosertib (ON 01910.Na) is a novel multi-kinase inhibitor initially developed as a non-ATP competitive agent, targeting dysregulated signalling pathways in cancer cells, notably RAS/RAF/MEK/ERK and PI3K/AKT, alongside Polo-like kinase 1 (PLK1). Preclinical st... ...
